MISSISSAUGA, Ontario and HELSINKI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Labquality Oy (Labquality), announce a novel external quality assessment (“EQA”) program to help ensure clinical laboratories accurately identify head and neck cancers associated with cancer-causing strains of Human Papilloma Virus (“HPV”). Labquality is introducing this novel EQA scheme at the 2025 meeting of the Europ ...